andyturbo
Administrator: PR.net
- Joined
- Dec 12, 2006
- Messages
- 4,395
3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review - PubMed
The Food and Drug Administration (FDA) granted breakthrough therapy status to 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) in 2017 due to preliminary evidence supporting its efficacy and safety in treating post-traumatic stress disorder (PTSD). A series of six phase-II clinical tri …
pubmed.ncbi.nlm.nih.gov
MDMA is being fast-tracked for potential FDA approval by 2023. 67% of patients who participated in 3 MDMA-assisted therapy sessions no longer met the criteria for PTSD. The effects are durable for at least four years but could last even longer.